Diagnostic tests and prognostic indictors

Imaging features of haematological malignancies of kidneys. Sandrasegaran K et al. Clin Radiol. 2015 Dec 11. pii: S0009-9260(15)00444-4. doi: 10.1016/j.crad.2015.11.007. [Epub ahead of print]. Minimal tumour burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? Pieri M et al. Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13878. [Epub ahead of print]. ANNALS EXPRESS: Low IgA levels…

Related conditions

Clinical features and prognostic factors in solitary plasmacytoma. Finsinger P et al. Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13870. [Epub ahead of print]. Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis. Paiva B et al. Blood. 2015 Dec 14. pii: blood-2015-10-662320. [Epub ahead of print]. Isolated Tricuspid Regurgitation: Initial Manifestation of Cardiac Amyloidosis.…

Emerging treatments

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study. Richardson PG et al. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16. Role of Histone Deacetylase Inhibitors in Relapsed Refractory Multiple Myeloma: A Focus on Vorinostat and Panobinostat. Afifi S et al. Pharmacotherapy. 2015 Dec;35(12):1173-88. doi:…

Biology and genetics

MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment. Gu C et al. Oncotarget. 2015 Dec 14. doi: 10.18632/oncotarget.6610. [Epub ahead of print]. Using “residual” FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience. Wei S et al. Cancer Cytopathol. 2015 Dec 18. doi: 10.1002/cncy.21666. [Epub ahead of print]. miR-186 inhibits cell proliferation in multiple myeloma by…

General

Immunotherapy: the next step in the treatment of myeloma. Palumbo A et al. Lancet Haematol. 2015 Dec;2(12):e504-5. doi: 10.1016/S2352-3026(15)00226-4. Epub 2015 Nov 16. Mobilization policy in multiple myeloma: minimum target or law of redundancy? Two different approaches by the two sides of the Atlantic Ocean. Olivieri A et al. Bone Marrow Transplant. 2015 Dec 21. doi: 10.1038/bmt.2015.317. [Epub ahead of print]. Cohort Profile:…

Complications of myeloma and its treatments

Diffuse normolipemic plane xanthoma associated with monoclonal gammopathy. Cohen YK et al. Dermatol Pract Concept. 2015 Oct 31;5(4):65-7. doi: 10.5826/dpc.0504a16. eCollection 2015. Plasmacytoma of the testis in a patient with relapsed and refractory multiple myeloma: Case report and review of the literature. Khan M et al. Urol Ann. 2015 Oct-Dec;7(4):530-3. doi: 10.4103/0974-7796.164844. Venous thromboembolism in hematopoietic stem cell transplant recipients. Chaturvedi S et…

Diagnostic tests and prognostic indicators

New patterns of relapse in multiple myeloma: a case of “light chain escape” in which FLC predicted relapse earlier than urine and serum immunofixation. Caldini A et al. Clin Chem Lab Med. 2015 Nov 18. pii: /j/cclm.ahead-of-print/cclm-2015-0689/cclm-2015-0689.xml. doi: 10.1515/cclm-2015-0689. [Epub ahead of print]. TLR4/TIRAP polymorphisms are associated with progression and survival of patients with symptomatic myeloma. Bagratuni T et al. Br J…

Emerging treatments

Oral Ixazomib Maintenance Therapy in Multiple Myeloma. Offidani M et al. Expert Rev Anticancer Ther. 2015 Nov 20. [Epub ahead of print]. Effective use of panobinostat in combination with other active agents in myeloma in a novel 5-drug combination: Case Report and Interesting Observations. Rajan AM et al. Am J Hematol. 2015 Nov 17. doi: 10.1002/ajh.24244. [Epub ahead of print]. Efficacy and safety of…